Cassiopea Partners acted as exclusive financial advisor to Minerva Hub S.p.A. (“Minerva Hub”), the industrial group backed by Xenon Private Equity S.A. (“Xenon”), in the acquisition of 100% share capital of Oroplac S.r.l. (“Oroplac”) through its controlled company Koverlux S.r.l.. Minerva Hub is one of the leading Italian platforms...
Cassiopea Partners acted as exclusive financial advisor to BP Italia S.p.A. (“BP Italia”), the Italian subsidiary of BP p.l.c. (“BP”), in the sale of a going concern including the oil blending site in Cornaredo (MI) (the “Going Concern”) to Foundry Alfe Chem S.r.l. (“Foundry Alfe Chem”). BP is the...
Cassiopea Partners acted as financial advisor to Named Group, the Italian market leader in dietary supplements, medical devices, and cosmetics, in the acquisition of 100% of the share capital of New Penta, a leading Italian integrated nutrition player, from Orienta Capital Partners and Mr. Guido Dracone. New Penta provides...
Cassiopea Partners, in association with its partner Strata Partners, acted as financial advisor to Aptos, LLC (“Aptos”) on the sale of its planning and product lifecycle management division (“Aptos’ Planning Division”) to US Software company Aptean Inc. (“Aptean”). Through the transaction, Aptean acquired the full breadth of operations and...
Cassiopea Partners acted as sole financial advisor to Eurizon ITEᴙ (“Eurizon”) infrastructure funds advised by ITEᴙ Capital Partners (“ITEᴙ”), in the acquisition of a majority stake in Trasporti Romagna S.p.A. (“Trasporti Romagna” or the “Group”), a leading T&L Italian group providing integrated transport and logistic services specialized in food...
Cassiopea Partners, jointly with Jefferies, acted as financial advisor to Fine PCB S.p.A. (together with its subsidiaries “Somacis” or the “Group”) and its shareholders, including Green Arrow Private Equity Fund 3 (“Green Arrow”), on the sale to Chequers Capital via Chequers Capital XVII FPCI fund (“Chequers Capital”). Founded in...
Cassiopea Partners acted as financial advisor to Novamont S.p.A. (“Novamont”) in the redefinition of the shareholder agreement between Mater-Bi S.p.A. and Versalis S.p.A. (“Versalis”), which will also imply an increase of Versalis’ stake in Novamont from 25% to 35%. Novamont is an international leading company in the bioplastics sector...
Cassiopea Partners acted as sole financial advisor to Mandarin Capital Partners II ("MCP II") and other shareholders in the sale of 100% of Mipharm (or the “Company”) to Alto Partners. Mipharm S.p.A. (“Mipharm” or the “Company”) is a Milan-based company recognized among the Italian leaders in the production of...
Cassiopea Partners acted as sole financial advisor to iCON Infrastructure in the acquisition of a 100% interest in Sestrieres S.p.A. ("Sestrieres" or the "Company") from its shareholders Pubbli-Gest S.p.A. and A.B.C. S.r.l.. Sestrieres, established in 1931 and headquartered in Sestriere in Piedmont, Italy, is the operator of one of...
Cassiopea Partners acted as sole financial advisor to White Bridge Investments and Biofarma Group (“Biofarma”) in the acquisition of a majority stake in International Health Science (“IHS” or the “Business Unit”), the finished products business division of Giellepi S.p.A. (“Giellepi”) and Italian leader in the development of nutraceutical dietary...
CASSIOPEA PARTNERS
Piazza Cavour, 1 20121, Milano, info@cassiopeapartners.com, Cassiopea Partners 2018 - P.I. 07930880963